Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinacalcet in Biochemically Recurrent Prostate Cancer
NCT01054079Phase 2Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Sep 2011
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cinacalcet in prostate cancer (PCa), sponsored by Wake Forest University Health Sciences. Primary endpoint: Rate of Rise of Serum PSA at 24 weeks. Started Sep 2011; status: completed.
02
Drugs
cinacalcet
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01054079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01054079.